



DEFENSE  
HEALTH AGENCY

HPOB

OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE  
HEALTH AFFAIRS  
16401 EAST CENTRETECH PARKWAY  
AURORA, CO 80011-9066

CHANGE 194  
6010.56-M  
SEPTEMBER 21, 2016

**PUBLICATIONS SYSTEM CHANGE TRANSMITTAL FOR  
TRICARE OPERATIONS MANUAL (TOM), FEBRUARY 2008**

The Defense Health Agency has authorized the following addition(s)/revision(s).

**CHANGE TITLE: LABORATORY DEVELOPED TESTS DEMONSTRATION PROJECTS**

**CONREQ: 18030**

**PAGE CHANGE(S): See page 2.**

**SUMMARY OF CHANGE(S): This change adds 25 Laboratory Developed Tests (LDTs), adds recommendations for coverage to already covered LDTs, and modifies the Current Procedural Terminology coding.**

**EFFECTIVE DATE: October 21, 2016.**

**IMPLEMENTATION DATE: October 21, 2016.**

LOZOYA.JOS  
E.L. 12314163  
97  
Digitally signed by  
LOZOYA.JOSE.L.1231416397  
DN: c=US, o=U.S. Government,  
ou=DoD, ou=PKI, ou=DHA,  
cn=LOZOYA.JOSE.L.1231416397  
Date: 2016.09.19 11:59:41 -0600

**John L. Arendale  
Section Chief, Health Plan  
Operations Branch (HPOB)  
Defense Health Agency (DHA)**

**CHANGE 194**  
**6010.56-M**  
**SEPTEMBER 21, 2016**

**REMOVE PAGE(S)**

**CHAPTER 18**

Section 17, pages 9 through 35

**INSERT PAGE(S)**

Section 17, pages 9 through 37

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED**

<b>GENE:</b>	<b>ALK</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	ALK gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To determine response to Tyrosine Kinase Inhibitor (TKI) therapy in patients with adenocarcinoma of the lung or mixed lung cancer with adenocarcinoma component of the lung.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	88271 Molecular cytogenetics; DNA probe, each (e.g., FISH) 88291 Cytogenetics and molecular cytogenetics, interpretation and report

<b>GENE:</b>	<b>APC</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	APC gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>Testing for APC variants in individuals with clinical symptoms consistent with Familial Adenomatous Polyposis (FAP).</li> <li>Testing for APC variants in individuals with clinical symptoms consistent with Attenuated Familial Adenomatous Polyposis (AFAP).</li> <li>Testing for APC variants in individuals with clinical symptoms consistent with Turcot's or Gardner's syndromes.</li> <li>Testing individuals with an APC-associated polyposis syndrome for the purpose of identifying a variant that may be used to screen at-risk relatives.</li> <li>For the presymptomatic testing of at-risk relatives for a known familial variant.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81201 APC (Adenomatous Polyposis Coli) (e.g., Familial Adenomatous Polyposis [FAP], attenuated FAP) gene analysis; full gene sequence 81202 known familial variants 81203 duplication/deletion variants

<b>GENE:</b>	<b>ATXN1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	ATXN1 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>Diagnosis of Spinocerebellar Ataxia Type 1 (SCA1) in patients with cerebellar ataxia of unknown etiology, along with extracerebellar symptoms associated with SCA1 and/or a family history consistent with autosomal dominant inheritance.</li> <li>Diagnosis of SCA1 in symptomatic family members of known SCA1 patients.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 ATXN1 (ataxin1) (e.g., spinocerebellar ataxia), evaluation to detect abnormal (e.g., expanded) alleles

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>ATXN2</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	ATXN2 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnosis of Spinocerebellar Ataxia Type 2 (SCA2) in patients with cerebellar ataxia of unknown etiology, along with extracerebellar symptoms associated with SCA2 and/or a family history consistent with autosomal dominant inheritance.</li> <li>• Diagnosis of SCA2 in symptomatic family members of known SCA2 patients.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 ATXN2 (ataxin2) (e.g., spinocerebellar ataxia), evaluation to detect abnormal (e.g., expanded) alleles

<b>GENE:</b>	<b>ATXN3</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	ATXN3 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnosis of Spinocerebellar Ataxia Type 3 (SCA3) in patients with cerebellar ataxia of unknown etiology, along with extracerebellar symptoms associated with SCA3 and/or a family history consistent with autosomal dominant inheritance.</li> <li>• Diagnosis of SCA3 in symptomatic family members of known SCA3 patients.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 ATXN3 (ataxin3) (e.g., spinocerebellar ataxia, Machado-Joseph disease), evaluation to detect abnormal (e.g., expanded) alleles

<b>GENE:</b>	<b>ATXN7</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	ATXN7 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnosis of Spinocerebellar Ataxia Type 7 (SCA7) in patients with cerebellar ataxia and visual disturbance.</li> <li>• Diagnosis of SCA7 in symptomatic family members of known SCA7 patients.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 ATXN7 (ataxin7) (e.g., spinocerebellar ataxia), evaluation to detect abnormal (e.g., expanded) alleles
<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.		

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>ATXN10</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	ATXN10 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnosis of Spinocerebellar Ataxia Type 10 (SCA10) in ataxia patients whose ancestry is of American Indian origin, and whose family history is consistent with autosomal dominant inheritance.</li> <li>• Diagnosis of SCA10 in symptomatic family members of known SCA10 patients.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 ATXN10 (ataxin10) (e.g., spinocerebellar ataxia), evaluation to detect abnormal (e.g., expanded) alleles

<b>GENE:</b>	<b>BCR/ABL1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	BCR/ABL1 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnostic assessment of individuals with suspected Chronic Myelogenous Leukemia (CML) by quantitative RT-PCR (RQ-PCR).</li> <li>• Diagnostic assessment of individuals with suspected CML by qualitative RT-PCR.</li> <li>• Monitoring response to TKI therapy, such as imatinib, in individuals with CML by RQ-PCR.</li> <li>• Testing for the presence of the BCR/ABL1 p.Thr315Ile variant in CML patients to guide treatment selection following resistance to first-line imatinib therapy.</li> <li>• Testing for the presence of BCR/ABL1 variants other than p.Thr315Ile in CML patients to guide treatment selection following resistance to first-line imatinib therapy.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81170 ABL1 81206 BCR/ABL1 gene major bp 81207 BCR/ABL1 gene minor bp 81208 BCR/ABL1 gene other bp

<b>GENE:</b>	<b>BMPR1A</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	BMPR1A gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• To clarify the diagnosis of individuals with Juvenile Polyposis Syndrome (JPS).</li> <li>• If a known SMAD4 mutation is in the family, genetic testing should be performed in the first six months of life due to hereditary hemorrhagic telangiectasia risk.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81479 Unlisted molecular pathology procedure

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>		<b>BRAF</b>	
Effective Date:	January 1, 2013		
Coverage Guidelines:	BRAF gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• To predict response to vemurafenib therapy in patients with a positive cobas 4800 BRAF mutation test result.</li> <li>• To predict response to trametinib monotherapy in advanced melanoma patients with a positive BRAF p.Val600Glu and/or p.Val600Lys test result.</li> <li>• To predict response to dabrafenib monotherapy in advanced melanoma patients with a positive BRAF p.Val600Glu test result.</li> <li>• To predict response to trametinib and dabrafenib combination therapy in advanced melanoma patients with a positive BRAF p.Val600Glu and/or p.Val600Lys test result.</li> <li>• For individuals with indeterminate thyroid Fine-Needle Aspiration (FNA) biopsy cytology for diagnosis of papillary thyroid carcinoma.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81210	BRAF gene

<b>GENE:</b>		<b>BRCA1/BRCA2</b>	
Effective Date:	January 1, 2013		
Coverage Guidelines:	BRCA1/BRCA2 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• For individuals from families transmitting a known BRCA1/2 variant.</li> <li>• For individuals with a history of breast cancer and at least one of the following:                             <ul style="list-style-type: none"> <li>• Breast cancer diagnosed ≤ 45 years of age.</li> <li>• Breast cancer diagnosed ≤ 50 years of age and a close family member with breast cancer.</li> <li>• Two breast primaries with one diagnosed at or before age 50.</li> <li>• A diagnosis of triple negative breast cancer at or before age 60.</li> </ul> </li> <li>• Breast cancer diagnosed at any age and at least one close relative with breast cancer before age 50 and/or epithelial ovarian cancer at any age.</li> <li>• Breast cancer diagnosed at any age and at least two close relatives diagnosed with breast, pancreatic, and/or prostate (Gleason ≥ 7) cancer at any age.</li> <li>• A close male relative, which includes first-, second-, and third-degree relatives, with breast cancer.</li> <li>• An ethnic background associated with a higher frequency of BRCA1/2 variants (i.e., Ashkenazi Jewish).</li> <li>• For individuals with a personal history of epithelial ovarian cancer.</li> <li>• For individuals with male breast cancer.</li> <li>• For individuals with a personal history of pancreatic cancer or prostate (Gleason ≥ 7) and at least two close relatives with breast, ovarian, prostate (Gleason ≥ 7), and/or pancreatic cancer.</li> </ul>		

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

Coverage Guidelines (Continued):	<ul style="list-style-type: none"> <li>For unaffected individuals (with no personal history of cancer) who have one of the following: <ul style="list-style-type: none"> <li>A first- or second-degree relative satisfying the above criteria.</li> <li>A third-degree relative with breast and/or ovarian cancer and at least two more relatives with breast cancer (at least one diagnosed before age 50) and/or ovarian cancer.</li> </ul> </li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	<p>81162 BRCA1&amp;2 seq &amp; full dup/del</p> <p>81211 BRCA1&amp;2 seq &amp; com dup/del</p> <p>81212 BRCA1&amp;2 185&amp;538&amp;6174 var</p> <p>81213 BRCA1&amp;2 uncom dup/del var</p> <p>81214 BRCA1 full seq &amp; com dup/del</p> <p>81215 BRCA1 gene known fam variant</p> <p>81216 BRCA2 gene full sequence</p> <p>81217 BRCA2 gene known fam variant</p>

<b>GENE:</b>	<b>CACNA1A</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	CACNA1A gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>Diagnosis of Spinocerebellar Ataxia Type 6 (SCA6) in patients with cerebellar ataxia with dysarthria and/or nystagmus.</li> <li>Diagnosis of SCA6 in symptomatic family members of known SCA6 patients.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 CACNA1A (calcium channel, voltage-dependent, P/Q type, alpha 1A subunit) (e.g., spinocerebellar ataxia), evaluation to detect abnormal (e.g., expanded) alleles

<b>GENE:</b>	<b>CALM1, CASQ2, RYR2, and TRDN</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	CALM1, CASQ2, RYR2, and TRDN gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To confirm a diagnosis of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) in patients with clinically diagnosed or suspected CPVT.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	<p>81405 Mopath procedure level 6</p> <p>81408 Mopath procedure level 9</p> <p>81479 Unlisted molecular pathology</p>

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>CDH1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	CDH1 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• For large rearrangements in the CDH1 gene for the treatment of Hereditary Diffuse Gastric Cancer (HDGC).</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81406 Mopath procedure level 7

<b>GENE:</b>	<b>CEBPA</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	CEBPA gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• To guide the treatment decisions for individuals with Acute Myeloid Leukemia (AML).</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81218 CEBPA gene full sequence

<b>GENE:</b>	<b>Chromosome 22q11.2</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	Chromosome 22q11.2 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• Confirmation of diagnosis in an individual suspected of chromosome 22q11.2 deletion syndrome based on clinical findings.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	88271 Molecular cytogenetics; DNA probe, each (e.g., FISH) 88291 Cytogenetics and molecular cytogenetics, interpretation and report

<b>GENE:</b>	<b>CFTR</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	CFTR gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Confirmation of diagnosis in individuals showing clinical symptoms of Cystic Fibrosis (CF) or having a high sweat chloride level.</li> <li>• Identification of newborns who are affected with CF.</li> <li>• Identification of individuals with the p.Gly551Asp variant who will respond to treatment with ivacaftor.</li> <li>• Male infertility testing and treatment.</li> <li>• Preconception and prenatal carrier screening in accordance with the most current ACOG guidelines.</li> </ul>	

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81220	CFTR (cystic fibrosis transmembrane conductance regulator) (e.g. cystic fibrosis) gene analysis, common variants
		81221	known familial variants
		81222	duplication/deletion variants
		81223	full gene sequence
		81224	intron 8 poly-T analysis (e.g. male infertility)

<b>GENE:</b>	<b>Chimerism Analysis</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	Chimerism analysis is covered for the following indication: <ul style="list-style-type: none"> <li>For the management and treatment of stem cell transplant patients.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81265	Str markers specimen anal
		81266	Str markers spec anal addl
		81267	Chimerism anal no cell selec
		81268	Chimerism anal w/cell select

<b>GENE:</b>	<b>COL1A1/COL1A2</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	COL1A1/COL1A2 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>For sequence variants in the COL1A1/COL1A2 genes for the diagnosis of Osteogenesis Imperfecta (OI) when clinical and radiological examination and family history provide inadequate information for diagnosis of OI.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81408	Mopath procedure level 9

<b>GENE:</b>	<b>COL3A1</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	COL3A1 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To confirm or establish a diagnosis of Ehlers-Danlos Syndrome Type 4 (EDS IV), also known as vascular EDS, in patients with clinical symptoms or features of EDS IV.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81479	Unlisted molecular pathology procedure

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>CYP2C9</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	CYP2C9 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• For the initiation and management of warfarin treatment.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81227 CYP2C9 gene com variants

<b>GENE:</b>	<b>CYP2C19</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	CYP2C19 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• To manage dosing of clopidogrel.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81225 CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *8, *17)

<b>GENE:</b>	<b>Cytogenomic Constitutional Microarray Analysis</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	Cytogenomic Constitutional Microarray Analysis gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnostic evaluation of patients suspected of having a genetic syndrome (i.e., have congenital anomalies, dysmorphic features, Developmental Delay (DD), and/or intellectual disability).</li> <li>• Diagnostic evaluation of individuals with Autism Spectrum Disorder (ASD), including autism, Asperger syndrome, and pervasive developmental disorder.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81228 Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (e.g., Bacterial Artificial Chromosome [BAC] or oligo-based Comparative Genomic Hybridization [CGH] microarray analysis)  81229 interrogation of genomic regions for copy number and Single Nucleotide Polymorphism (SNP) variants for chromosomal abnormalities  81406 Cytogenomic microarray analysis, neoplasia (e.g., interrogation of copy number, and loss-of-heterozygosity via Single Nucleotide Polymorphism [SNP]-based Comparative Genomic Hybridization [CGH] microarray analysis)

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>DAZ/SRY</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	DAZ/SRY gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To detect submicroscopic deletions involving the Y chromosome in the evaluation of men with infertility secondary to azoospermia, oligozoospermia, or teratozoospermia.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81403 DAZ/SRY (deleted in azoospermia and sex determining region Y) (e.g., male infertility), common deletions (e.g., AZFa, AZFb, AZFc, AZFd)

<b>GENE:</b>	<b>DMD</b>	
Effective Date:	November 20, 2014	
Coverage Guidelines:	DMD gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>For diagnostic DMD testing (deletion and duplication analysis with reflex to complete gene sequencing) in males or females exhibiting symptoms of Duchenne Muscular Dystrophy (DMD) or Becker Muscular Dystrophy (BMD).</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81161 DMD dup/delet analysis 81408 Mopath procedure level 9

<b>GENE:</b>	<b>DMPK</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	DMPK gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>Confirmation of a diagnosis of Myotonic Dystrophy Type 1 (DM1) or Type 2 (DM2) in symptomatic patients.</li> <li>Diagnosis of DM1 or DM2 in asymptomatic adults who are at an increased risk of DM1 or DM2 through a positive family history.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 DMPK (dystrophia myotonica-protein kinase) (e.g., myotonic dystrophy, type 1), evaluation to detect abnormal (e.g., expanded) alleles  81404 DMPK (dystrophia myotonica-protein kinase) (e.g., myotonic dystrophy type 1), characterization of abnormal (e.g., expanded) alleles

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>DSC2, DSG2, DSP, JUP, PKP2, RYR2, TGFB3, and TMEM43</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>DSC2, DSG2, DSP, JUP, PKP2, RYR2, TGFB3, and TMEM43 gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• For sequence variants in the DSC2, DSG2, DSP, JUP, PKP2, RYR2, TGFB3, and TMEM43 genes to confirm a diagnosis of Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy (ARVD/C) in probands.</li> <li>• For a known familial sequence variant in the DSC2, DSG2, DSP, PKP2, or TMEM43 gene for at-risk relatives of probands with International Task Force (ITF)-confirmed ARVD/C to confirm a diagnosis of ARVD/C in those whose symptoms meet the ITF diagnostic criteria.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	<p>81406 Mopath procedure level 7</p> <p>81408 Mopath procedure level 9</p>

<b>GENE:</b>	<b>EGFR</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>EGFR gene testing is covered for the following indication:</p> <ul style="list-style-type: none"> <li>• To help guide administration of Epidermal Growth Factor Receptor (EGFR) TKIs in the first-line treatment of non-small cell lung cancer.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81235 EGFR (epidermal growth factor receptor) (e.g. non-small cell lung cancer) gene analysis, common variants (e.g. exon 19 LREA deletion, L858R, T790M, G719A, G719S, L861Q)

<b>GENE:</b>	<b>F2</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>Prothrombin (Factor II) related thrombophilia gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• Diagnostic evaluation of individuals with a prior Venous Thromboembolism (VTE) during pregnancy or puerperium.</li> <li>• For patients with VTE with a personal or family history of recurrent VTE (more than two in the same person).</li> <li>• For patients with their first VTE before age 50 with no precipitating factors.</li> <li>• For venous thrombosis at unusual sites such as the cerebral, mesenteric, portal, or hepatic veins.</li> <li>• For VTE associated with the use of estrogen-containing oral contraceptives, Selective Estrogen Receptor Modulators (SERMs), or Hormone Replacement Therapy (HRT).</li> <li>• To diagnose an inherited thrombophilia in female family members of individuals with an inherited thrombophilia if the female family member is pregnant or considering pregnancy or oral contraceptive use.</li> </ul>	

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81240	F2 (prothrombin, coagulation factor II) (e.g., hereditary hypercoagulability) gene analysis, 20210G>A variant
		81400	F2 (coagulation factor 2) (e.g., hereditary hypercoagulability), 1199G>A variant

<b>GENE:</b>	<b>FBN1</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	<p>FBN1 gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>To facilitate the diagnosis of Marfan syndrome in patients who do not fulfill the Ghent diagnostic criteria, but have at least one major feature of the condition.</li> <li>To facilitate the diagnosis of Marfan syndrome in the at-risk relatives of patients carrying known disease-causing variants.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81408	FBN1 (fibrillin 1) (e.g., Marfan syndrome), full gene sequence

<b>GENE:</b>	<b>FLCN</b>		
Effective Date:	July 31, 2014		
Coverage Guidelines:	<p>FLCN gene testing is covered for the following indication:</p> <ul style="list-style-type: none"> <li>To confirm a diagnosis of Birt-Hogg-Dubé Syndrome (BHD) in patients with suspected BHD.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81479	Unlisted molecular pathology

<b>GENE:</b>	<b>FLT3</b>		
Effective Date:	October 7, 2013		
Coverage Guidelines:	<p>FLT3 gene testing is covered for the following indication:</p> <ul style="list-style-type: none"> <li>For diagnosis and prognosis in AML.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81245	FLT3 gene
		81246	FLT3 gene analysis

<b>GENE:</b>	<b>F5</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	<p>Factor V Leiden thrombophilia gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>Diagnostic evaluation of individuals with a prior VTE during pregnancy or puerperium.</li> <li>For patients with VTE with a personal or family history of recurrent VTE (more than two in the same person).</li> <li>For patients with their first VTE before age 50 with no precipitating factors.</li> </ul>		

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

Coverage Guidelines (Continued):	<ul style="list-style-type: none"> <li>For venous thrombosis at unusual sites such as the cerebral, mesenteric, portal, or hepatic veins.</li> <li>For VTE associated with the use of estrogen-containing oral contraceptives, Selective Estrogen Receptor Modulators (SERMs), or Hormone Replacement Therapy (HRT).</li> <li>To diagnose an inherited thrombophilia in female family members of individuals with an inherited thrombophilia if the female family member is pregnant or considering pregnancy or oral contraceptive use.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81241 F5 (coagulation factor V) (e.g., hereditary hypercoagulability) gene analysis, Leiden variant  81400 F5 (coagulation factor V) (e.g., hereditary hypercoagulability), HR2 variant

<b>GENE:</b>	<b>FMR1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	FMR1 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>Testing for CGG repeat length for diagnosis of patients of either sex with mental retardation, intellectual disability, developmental delay, or autism.</li> </ul> FMR1 gene testing for Fragile X-Associated Tremor/Ataxia Syndrome is covered for the following individuals: <ul style="list-style-type: none"> <li>Males and females older than age 50 years who have progressive cerebellar ataxia and intention tremor with or without a positive family history of FMR1-related disorders in whom other common causes of ataxia have been excluded.</li> <li>Women with unexplained Premature Ovarian Insufficiency (POI).</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81243 FMR1 (fragile X mental retardation 1) (e.g., fragile X mental retardation) gene analysis; evaluation to detect abnormal (e.g., expanded) alleles 81244 characterization of alleles (e.g., expanded size and methylation status)

<b>GENE:</b>	<b>GCK</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	GCK gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>Diagnosis of Maturity-Onset Diabetes of the Young Type 2 (MODY2) in patients with hyperglycemia or non-insulin-dependent diabetes who have a family history of abnormal glucose metabolism in at least two consecutive generations, with the patient or ≥ 1 family member(s) diagnosed before age 25.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81406 GCK (glucokinase [hexokinase 4]) (e.g., maturity-onset diabetes of the young [MODY]), full gene sequence

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>GJB2</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	GJB2 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• Diagnosis of DFNB1 or DFNA3 in individuals with nonsyndromic hearing loss to aid in treatment.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81252 GJB2 (gap junction protein, beta 2, 26kDa, connexin 26) (e.g., nonsyndromic hearing loss) gene analysis; full gene sequence  81253 known familial variants

<b>GENE:</b>	<b>GJB6</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	GJB6 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• Diagnosis of DFNB1 or DFNA3 in individuals with nonsyndromic hearing loss to aid in treatment.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81254 GJB6 (gap junction protein, beta 6, 30kDa, connexin 30) (e.g., nonsyndromic hearing loss) gene analysis, common variants (e.g., 309kb [del(GJB6-D13S1830)] and 232kb [del(GJB6-D13S1854)])

<b>GENE:</b>	<b>HBA1/HBA2</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	HBA1/HBA2 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• To confirm the diagnosis of alpha-thalassemia in a symptomatic individual.</li> <li>• To confirm the diagnosis in a pregnant woman with low hemoglobin when alpha-thalassemia is suspected.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81257 HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia, Hb Bart hydrops fetalis syndrome, HbH disease), gene analysis, for common deletions or variant (e.g., Southeast Asian, Thai, Filipino, Mediterranean, alpha3.7, alpha4.2, alpha20.5, and Constant Spring)  81404 HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia), duplication/deletion analysis  81405 HBA1/HBA2 (alpha globin 1 and alpha globin 2) (e.g., alpha thalassemia), full gene sequence

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>		<b>HEXA</b>	
Effective Date:	January 1, 2013		
Coverage Guidelines:	HEXA gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>As an adjunct to biochemical testing in patients with low hexosaminidase A levels in blood. When individuals are identified with apparent deficiency of hexosaminidase A enzymatic activity, targeted mutation analysis can then be used to distinguish pseudodeficiency alleles from disease-causing alleles.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81255	HEXA (hexosaminidase A [alpha polypeptide]) (e.g., Tay-Sachs disease) gene analysis, common variants (e.g., 1278insTATC, 1421+1G>C, G269S)
		81406	HEXA (hexosaminidase A, alpha polypeptide) (e.g., Tay-Sachs disease), full gene sequence

<b>GENE:</b>		<b>HFE</b>	
Effective Date:	January 1, 2013		
Coverage Guidelines:	HFE-associated hereditary hemochromatosis gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>Diagnosis of patients with or without symptoms of iron overload with a serum transferrin saturation &gt;45% and/or elevated serum ferritin.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81256	HFE (hemochromatosis) (e.g., hereditary hemochromatosis) gene analysis, common variants (e.g., C282Y, H63D)

<b>GENE:</b>		<b>HLA</b>	
Effective Date:	January 1, 2013		
Coverage Guidelines:	HLA gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>To determine histocompatibility of tissue between organ and bone marrow donors and recipients prior to transplant.</li> <li>For platelet transfusion for patients refractory to treatment due to alloimmunization.</li> <li>Diagnosis of celiac disease in symptomatic patients with equivocal results on small bowel biopsy and serology, or in previously symptomatic patients who are asymptomatic while on a gluten-free diet.</li> <li>Testing for the HLA-B*1502 allele prior to initiating treatment with carbamazepine in patients from high-risk ethnic groups.</li> <li>Testing for the HLA-B*5701 allele for hypersensitivity reactions in patients prior to initiation or reinitiation with treatments containing abacavir.</li> <li>Testing for the HLA-B*58:01 allele in patients prior to initiating treatment with allopurinol.</li> </ul>		

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81370	HLA Class I and II typing, low resolution (e.g. antigen equivalents); HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1
		81371	HLA-A, -B, and -DRB1 (e.g., verification typing)
		81372	HLA Class I typing, low resolution (e.g. antigen equivalents); complete (i.e., HLA-A, -B, and -C)
		81373	one locus (e.g., HLA-A, -B, or -C) each
		81374	one antigen equivalent (e.g. B*27), each
		81375	HLA Class II typing, low resolution (e.g. antigen equivalents); HLA-DRB1/3/4/5 and -DQB1
		81376	one locus (e.g., HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each
		81377	one antigen equivalent, each
		81378	HLA Class I and II typing, high resolution (i.e., alleles or allele groups), HLA-A, -B, -C, and -DRB1
		81379	HLA Class I typing, high resolution (i.e., alleles or allele groups); complete (i.e., HLA-A, -B, and -C)
		81380	one locus (e.g., HLA-A, -B, or -C), each
		81381	one allele or allele group (e.g., B*57:01P), each
		81382	HLA Class II typing, high resolution (i.e., alleles or allele groups); one locus (e.g., HLA-DRB1, -DRB3/4/5, -DQB1, -DQA1, -DPB1, or -DPA1), each
		81383	one allele or allele group (e.g., HLA- DQB1*06:02P), each

<b>GENE:</b>	<b>HNF1A</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	HNF1A gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• Diagnosis of Maturity-Onset Diabetes of the Young Type 3 (MODY3) in patients with hyperglycemia or non-insulin-dependent diabetes who have a family history of abnormal glucose metabolism in at least two consecutive generations, with the patient or ≥ 1 family member(s) diagnosed before age 25.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81405	HNF1A (HNF1 homeobox A) (e.g., maturity-onset diabetes of the young [MODY]), full gene sequence

<b>GENE:</b>	<b>HTT</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	HTT gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• To test for CAG repeat length for diagnosis of Huntington Chorea/Disease (HD) in patients suspected of having HD in the absence of a family history of HD.</li> </ul>		

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401	HTT (huntington) (e.g., Huntington disease), evaluation to detect abnormal (e.g., expanded) alleles
--	-----------------------	-------	---

<b>GENE:</b>	<b>IGH</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	IGH gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• For medical management of patients with Acute Lymphoblastic Leukemia (ALL) through analysis of rearrangements in the IGH gene to estimate Minimal Residual Disease (MRD) levels.</li> <li>• For diagnostic evaluation of rearrangements in the IGH gene in patients with suspected B-cell Non-Hodgkin's Lymphoma (NHL), but in whom clinical, immunophenotypic, and histologic evaluation have provided inconclusive results.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81261	IGH gene rearrange amp meth
		81262	IGH gene rearrang dir probe
		81263	IGH vari regional mutation

<b>GENE:</b>	<b>IGK</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	IGK gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• For medical management of patients with ALL through analysis of rearrangements in the IGK gene to estimate MRD levels.</li> <li>• For diagnostic evaluation of rearrangements in the IGK gene in patients with suspected B-cell NHL, but in whom clinical, immunophenotypic, and histologic evaluation have provided inconclusive results.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81264	IGK rearrangeabn clonal pop

<b>GENE:</b>	<b>JAK2</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	JAK2 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnostic evaluation of individuals presenting with clinical, laboratory, or pathological findings suggesting classic forms of myeloproliferative neoplasms (MPN), that is, Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Primary Myelofibrosis (PMF).</li> <li>• Diagnostic evaluation of PV through JAK2 Exon 12 variant detection in JAK2 p.Val617Phe negative individuals.</li> </ul>		

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81270	JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder) gene analysis, p.Val617Phe (V617F) variant
		81403	JAK2 (Janus kinase 2) (e.g., myeloproliferative disorder), exon 12 sequence and exon 13 sequence, if performed

<b>GENE:</b>	<b>KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>For patients with suspected familial Long QT Syndrome for confirmation of diagnosis and treatment.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81280	Long QT syndrome gene analysis (e.g., KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C, CAV3, SCN4B, AKAP, SNTA1, and ANK2); full gene sequence
		81281	known familial sequence variant
		81282	duplication/deletion variants

<b>GENE:</b>	<b>KIT</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	KIT gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>To confirm a diagnosis of a gastrointestinal stromal tumor (GIST) in patients who are negative by immunostaining.</li> <li>To determine primary resistance to treatment with TKIs in patients with an advanced metastatic or unresectable GIST.</li> <li>To determine primary resistance to preoperative or postoperative treatment of a GIST with TKIs.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81272	Kit gene targeted seq analysis
		81273	Kit gene analysis d816 variant

<b>GENE:</b>	<b>KRAS</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	KRAS gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To help guide administration of anti-EGFR monoclonal antibodies.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81275	KRAS gene variants <b>exon 2</b>
		81276	<b>KRAS gene addl variants</b>

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>MECP2</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	<p>MECP2 gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• Testing for MECP2 sequence variants in patients who meet established clinical diagnostic criteria for classic or variant Rett Syndrome (RS).</li> <li>• Testing for MECP2 sequence variants in patients who have symptoms of RS, but do not meet established clinical diagnostic criteria.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81302	MECP2 (methyl CpG binding protein 2) (e.g., Rett syndrome) gene analysis; full sequence analysis
		81303	known familial variant
		81304	duplication/deletion variants

<b>GENE:</b>	<b>MLH1, MSH2, MSH6, MSI, PMS2, and EPCAM</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	<p>Genetic testing for Lynch syndrome is covered for a <b>symptomatic or asymptomatic</b> beneficiary who meets one of the following criteria:</p> <p>1. <u>Amsterdam II criteria for Lynch syndrome genetic testing.</u></p> <p>At least three relatives of the affected beneficiary must have a cancer associated with Lynch syndrome; and all of the following criteria must be present:</p> <ul style="list-style-type: none"> <li>• One must be a first-degree relative of the other two;</li> <li>• At least two successive generations must be affected;</li> <li>• At least one relative with cancer associated with Lynch syndrome should be diagnosed before age 50 years;</li> <li>• FAP should be excluded in the colorectal cancer case(s) (if any); and</li> <li>• Tumors should be verified whenever possible.</li> </ul> <p>2. <u>Revised Bethesda guidelines:</u></p> <ul style="list-style-type: none"> <li>• Colorectal cancer diagnosed in a beneficiary at less than 50 years of age.</li> <li>• Presence of synchronous or metachronous Lynch syndrome-associated cancers, regardless of age. Lynch syndrome-associated cancers include colorectal endometrial, ovarian, gastric, pancreas, ureter and renal pelvis, biliary tract, brain (usually glioblastoma), and small intestine cancers, as well as sebaceous gland adenomas/carcinomas and keratoacanthomas.</li> <li>• Colorectal cancer with the MSI-H histology diagnosed in a beneficiary who is less than 60 years of age.</li> <li>• Colorectal cancer diagnosed in a beneficiary with one or more first-degree relatives with a Lynch syndrome-associated cancer, with one of the cancers being diagnosed under age 50 years.</li> <li>• Colorectal cancer diagnosed in a beneficiary with two or more first- or second-degree relatives with Lynch syndrome-associated cancers, regardless of age.</li> </ul>		

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<p>Coverage Guidelines (Continued):</p>	<p>3. Has a known Lynch syndrome <b>mutation</b> in the family.</p> <p>4. Endometrial cancer diagnosed in a beneficiary at less than 50 years of age.</p> <p>5. If any of the revised Bethesda guidelines are met, Microsatellite Instability (MSI) and/or Immunohistochemistry (IHC) testing on the colon cancer tissue may be clinically appropriate. If the tumor is MSI positive or mutation of one of the mismatch repair genes is indicated by failure of IHC staining, then genetic testing should be undertaken. Further unnecessary testing can often be avoided by performance of IHC prior to any MSI testing.</p> <ul style="list-style-type: none"> <li>Genetic testing is covered for symptomatic or asymptomatic patients &gt; 18 years of age who are at risk of having a known familial sequence variant in a Mismatch Repair (MMR) gene.</li> </ul>	
<p>CPT Coding When Clinically Indicated By Coverage Guidelines:</p>	<p>CPT<sup>1</sup> Code</p>	<p><b>81288 MLH1 gene</b></p> <p>81292 MLH1 gene full seq</p> <p>81293 <b>MLH1 gene</b> known variants</p> <p>81294 <b>MLH1 gene</b> dup/delete variant</p> <p>81295 MSH2 gene full seq</p> <p>81296 <b>MSH2 gene</b> known variants</p> <p>81297 <b>MSH2 gene</b> dup/delete variant</p> <p>81298 MSH6 gene full seq</p> <p>81299 <b>MSH6 gene</b> known variants</p> <p>81300 <b>MSH6 gene</b> dup/delete variant</p> <p>81301 Microsatellite instability</p> <p>81317 PMS2 gene full seq</p> <p>81318 <b>PMS2 gene</b> known familial variants</p> <p>81319 <b>PMS2 gene</b> dup/delete variants</p> <p>81403 <b>Mopath procedure level 4</b></p>

<b>GENE:</b>	<b>MPL</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>MPL gene testing is covered for the following indication:</p> <ul style="list-style-type: none"> <li>Diagnostic evaluation of Myeloproliferative Leukemia (MPL) variants to include Trp515Leu and Trp515Lys in JAK2 p.Val617Phe-negative individuals showing symptoms.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	<p>81402 MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (e.g., myeloproliferative disorder), common variants (e.g., W515A, W515K, W515L, W515R)</p> <p>81403 MPL (myeloproliferative leukemia virus oncogene, thrombopoietin receptor, TPOR) (e.g., myeloproliferative disorder), exon 10 sequence</p>

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>MUTYH</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	MUTYH or MYH gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnosis of MYH-Associated Polyposis (MAP) in APC-negative colorectal polyposis patients, or in polyposis patients who have a family history consistent with autosomal recessive inheritance.</li> <li>• Diagnosis of MAP in asymptomatic siblings of patients with known MYH variants.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 MUTYH (mutY homolog [E. coli]) (e.g., MYH-associated polyposis), common variants (e.g., Y165C, G382D)  81406 MUTYH (mutY homolog [E. coli]) (e.g., MYH-associated polyposis), full gene sequence

<b>GENE:</b>	<b>Noninvasive Prenatal Screening for Trisomies 13, 18, 21, X &amp; Y</b>	
Effective Date:	March 5, 2015	
Coverage Guidelines:	Noninvasive Prenatal Screening for Trisomies 13, 18, 21, X & Y is covered for the following indication: <ul style="list-style-type: none"> <li>• In singleton pregnancies with a high risk of fetal aneuploidy.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81420 Fetal chromosomal aneuploidy 81479 Unlisted molecular pathology 81507 Fetal aneuploidy trisomy risk 81599 Unlisted maa

<b>GENE:</b>	<b>NPM1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	NPM1 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• To guide treatment decisions for individuals with AML.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81310 NPM1 (nucleophosmin) (e.g., acute myeloid leukemia) gene analysis, exon 12 variants

<b>GENE:</b>	<b>NRAS</b>	
Effective Date:	October 3, 2014	
Coverage Guidelines:	NRAS gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• For patients with metastatic colorectal cancer who are being considered for treatment with anti-EGFR monoclonal antibodies, and who have had negative KRAS gene testing.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81311 NRAS gene variants exon 2&3

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>Oncotype DX® Breast Cancer Assay (Oncotype DX®)</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>Oncotype DX® is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• Estrogen Receptor (ER) positive (+), lymph node (LN) negative (-), human EGFR 2 negative (HER2-) breast cancer patients who are considering whether to use adjuvant chemotherapy in addition to standard hormone therapy.</li> <li>• ER+, HER2- breast cancer patients with 1-3 involved ipsilateral axillary lymph nodes who are considering whether to use adjuvant chemotherapy in addition to hormonal therapy.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81519 Oncology breast <b>maa</b>

<b>GENE:</b>	<b>PAX8</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>PAX8 gene testing is covered for the following indication:</p> <ul style="list-style-type: none"> <li>• For individuals with indeterminate thyroid FNA biopsy cytology for diagnosis of papillary thyroid carcinoma.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 PAX8/PPARG (t(2;3) (q13;p25)) (e.g., follicular thyroid carcinoma), translocation analysis

<b>GENE:</b>	<b>PDGFRA</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>PDGFRA gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• To confirm a diagnosis of a GIST in patients who are negative by immunostaining.</li> <li>• To determine primary resistance to treatment with TKIs in patients with an advanced metastatic or unresectable GIST.</li> <li>• To determine primary resistance to preoperative or postoperative treatment of a GIST with TKIs.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	<b>81314 PDGFRA gene</b>

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>PML/RARalpha</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	PML/RARalpha gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnostic assessment of individuals with suspected acute promyelocytic leukemia (APL) by quantitative RT-PCR (RQ-PCR).</li> <li>• Diagnostic assessment of individuals with suspected APL by qualitative RT-PCR.</li> <li>• Monitoring response to treatment and disease progression in individuals with APL by RQ-PCR.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81315 PML/RARalpha, (t(15;17)), promyelocytic leukemia/retinoic acid receptor alpha (e.g., promyelocytic leukemia) translocation analysis; common breakpoints (e.g. intron 3 and intron 6), qualitative or quantitative  81316 single breakpoint (e.g., intron 3, intron 6 or exon 6), qualitative or quantitative

<b>GENE:</b>	<b>PMP22</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	PMP22 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• For the accurate diagnosis and classification of hereditary polyneuropathies.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81324 PMP22 (peripheral myelin protein 22) (e.g. Charcot-Marie-Tooth, hereditary neuropathy with liability to pressure palsies) gene analysis; duplication/deletion analysis  81325 full sequence analysis  81326 known familial variant

<b>GENE:</b>	<b>PPP2R2B</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	PPP2R2B gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnosis of Spinocerebellar Ataxia Type 12 (SCA12) in patients with action tremor of the upper extremities and signs of cerebellar and cortical dysfunction, in addition to Indian ancestry and a family history consistent with autosomal dominant inheritance.</li> <li>• Diagnosis of SCA12 in symptomatic family members of known SCA12 patients.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 PPP2R2B (protein phosphatase 2, regulatory subunit B, beta) (e.g., spinocerebellar ataxia), evaluation to detect abnormal (e.g., expanded) alleles

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>PRSS1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>PRSS1 gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• To confirm a diagnosis of hereditary pancreatitis in symptomatic patients with any of the following: <ul style="list-style-type: none"> <li>• A family history of pancreatitis in a first-degree (parent, sibling, child) or second-degree (aunt, uncle, grandparent) relative;</li> <li>• An unexplained episode of documented pancreatitis occurring in a child that has required hospitalization, and where there is significant concern that hereditary pancreatitis should be excluded;</li> <li>• Recurrent (two or more separate, documented episodes with hyper-amylasemia) attacks of acute pancreatitis for which there is no explanation (anatomical anomalies, ampullary or main pancreatic strictures, trauma, viral infection, gallstones, alcohol, drugs, hyperlipidemia, etc.); or</li> <li>• Unexplained (idiopathic) chronic pancreatitis.</li> </ul> </li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 PRSS1 (protease, serine, 1 [trypsin 1]) (e.g., hereditary pancreatitis), common variants (e.g., N29I, A16V, R122H)

<b>GENE:</b>	<b>PTEN</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>PTEN gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• For patients with ASDs and macrocephaly (Head circumference greater than 2 standard above the mean for age).</li> <li>• PTEN variant testing in individuals suspected of being affected with Cowden Syndrome (CS) or Bannayan-Riley-Ruvalcaba Syndrome (BRRS).</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	<p>81321 PTEN (phosphatase and tensin homolog) (e.g. Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis</p> <p>81322 known familial variant</p> <p>81323 duplication/deletion variant</p>

<b>GENE:</b>	<b>RET</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	<p>RET gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• Multiple endocrine neoplasia type 2 (MEN2) gene testing in patients with the clinical manifestations of MEN2A, MEN2B, or familial medullary thyroid carcinoma (FMTC), including those with apparently sporadic Medullary Thyroid Carcinoma (MTC) or pheochromocytoma.</li> <li>• MEN2 gene testing to confirm a diagnosis in the at-risk relatives of genetically confirmed MEN2 patients.</li> </ul>	

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81404	RET (ret proto-oncogene) (e.g., multiple endocrine neoplasia, type 2B and familial medullary thyroid carcinoma), common variants (e.g., M918T, 2647_2648delinsTT, A883F)
		81405	RET (ret proto-oncogene) (e.g., multiple endocrine neoplasia, type 2A and familial medullary thyroid carcinoma), targeted sequence analysis (e.g., exons 10, 11, 13-16)

<b>GENE:</b>	<b>ROS1</b>		
Effective Date:	January 12, 2016		
Coverage Guidelines:	ROS1 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>For patients who have wild type (negative) EGFR or ALK gene testing, reflex testing to ROS1 should be ordered for the treatment of non-small cell lung carcinoma.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	88274	Cytogenetics 25-99

<b>GENE:</b>	<b>RYR1</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	RYR1 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>To test clinically confirmed Malignant Hyperthermia Susceptibility (MHS) patients for variants in the RYR1 gene to facilitate diagnostic testing in at-risk relatives.</li> <li>To diagnose MHS in at-risk relatives of patients with clinically confirmed MHS.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81408	RYR1 (ryanodine receptor 1, skeletal) (e.g., malignant hyperthermia), full gene sequence

<b>GENE:</b>	<b>SDHB</b>		
Effective Date:	June 16, 2014		
Coverage Guidelines:	SDHB gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To diagnose a hereditary paraganglioma (PGL) or pheochromocytoma (PCC) syndrome in patients with PGLs and/or PCCs.</li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81405	SDHB (succinate dehydrogenase complex, subunit B, iron sulfur) (e.g., hereditary paraganglioma), full gene sequence

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>SDHD</b>	
Effective Date:	June 16, 2014	
Coverage Guidelines:	SDHD gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To diagnose a hereditary PGL or PCC syndrome in patients with PGLs and/or PCCs.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81404 SDHD (succinate dehydrogenase complex, subunit D, integral membrane protein) (e.g., hereditary paraganglioma), full gene sequence

<b>GENE:</b>	<b>SERPINA1</b>	
Effective Date:	May 27, 2014	
Coverage Guidelines:	SERPINA1 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>For guidance in diagnosis of inconclusive cases of Alpha-1 Antitrypsin Deficiency (AATD) in individuals with Chronic Obstructive Pulmonary Disease (COPD), unexplained liver disease, family history of AATD, or environmental exposures leading to airflow obstruction after serum Alpha-1 Antitrypsin (AAT) protein levels and protein phenotyping has been completed.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81332 SERPINA1 gene

<b>GENE:</b>	<b>SMAD4</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	SMAD4 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>To clarify the diagnosis of individuals with JPS.</li> <li>If a known SMAD4 mutation is in the family, genetic testing should be performed in the first six months of life due to hereditary hemorrhagic telangiectasia risk.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81405 SMAD4 (SMAD family member 4) (e.g., hemorrhagic telangiectasia syndrome, juvenile polyposis), duplication/deletion analysis  81406 SMAD4 (SMAD family member 4) (e.g., hemorrhagic telangiectasia syndrome, juvenile polyposis), full gene sequence

<b>GENE:</b>	<b>SMN1/SMN2</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	SMN1/SMN2 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>Diagnosis of patients with hypotonia and muscle weakness who are suspected of having Spinal Muscular Atrophy (SMA).</li> </ul>	

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81400	SMN1 (survival of motor neuron 1, telomeric) (e.g., spinal muscular atrophy), exon 7 deletion
		81401	SMN1/SMN2 (survival of motor neuron 1, telomeric/survival of motor neuron 2, centromeric) (e.g., spinal muscular atrophy), dosage analysis (e.g. carrier testing)
		81403	SMN1 (survival of motor neuron 1, telomeric) (e.g., spinal muscular atrophy), known familial sequence variant(s)
		81405	SMN1 (survival of motor neuron 1, telomeric) (e.g., spinal muscular atrophy), full gene sequence

<b>GENE:</b>	<b>SNRPN/UBE3A</b>		
Effective Date:	January 1, 2013		
Coverage Guidelines:	<p>SNRPN/UBE3A gene testing is covered for the following indications:</p> <ul style="list-style-type: none"> <li>• When a clinical diagnosis of Prader-Willi Syndrome (PWS) is suspected, the following findings justify genetic testing: <ul style="list-style-type: none"> <li>• From birth to age two: Hypotonia with poor suck (neonatal period).</li> <li>• From age two to age six: Hypotonia with history of poor suck, global developmental delay.</li> <li>• From age six to age 12: Hypotonia with history of poor suck, global developmental delay, excessive eating with central obesity if uncontrolled.</li> <li>• From age 13 years to adulthood: Cognitive impairment, usually mild intellectual disability; excessive eating with central obesity if uncontrolled, hypothalamic hypogonadism and/or typical behavior problems.</li> </ul> </li> <li>• When a clinical diagnosis of Angelman Syndrome is suspected, the following findings justify genetic testing: <ul style="list-style-type: none"> <li>• As part of the evaluation of patients with developmental delay, regardless of age.</li> <li>• As part of the evaluation of patients with a balance or movement disorder such as ataxia of gait. May not appear as frank ataxia but can be forward lurching, unsteadiness, clumsiness, or quick, jerky motions.</li> <li>• As part of the evaluation of patients with uniqueness of behavior: any combination of frequent laughter/smiling; apparent happy demeanor; easily excitable personality, often with uplifted hand-flapping or waving movements; hypermotoric behavior.</li> <li>• Speech impairment, none or minimal use of words; receptive and non-verbal communication skills higher than verbal ones.</li> </ul> </li> </ul>		
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81331	SNRPN/UBE3A (small nuclear ribonucleoprotein polypeptide N and ubiquitin protein ligase E3A) (e.g., Prader-Willi syndrome and/or Angelman syndrome), methylation analysis
<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.			

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>STK11</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	STK11 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>To confirm a diagnosis of Peutz-Jeghers Syndrome (PJS) in proband patients with a presumptive or probable diagnosis of PJS.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81404 STK11 (serine/threonine kinase 11) (e.g., Peutz-Jeghers syndrome), duplication/deletion analysis  81405 STK11 (serine/threonine kinase 11) (e.g., Peutz-Jeghers syndrome), full gene sequence

<b>GENE:</b>	<b>TBP</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	TBP gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>Diagnosis of Spinocerebellar Ataxia Type 17 (SCA17) in ataxia patients exhibiting variable combinations of cognitive decline, psychiatric disturbance, and movement disorders.</li> <li>Diagnosis of SCA17 in symptomatic family members of known SCA17 patients.</li> <li>Diagnosis of SCA17 in patients suspected of having Huntington Disease (HD) who have tested negative for a pathogenic variant in the HD gene.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81401 TBP (TATA box binding protein) (e.g., spinocerebellar ataxia), evaluation to detect abnormal (e.g., expanded) alleles

<b>GENE:</b>	<b>TP53</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	TP53 gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>Diagnosis of patients satisfying the criteria for classic Li-Fraumeni Syndrome (LFS) or Li-Fraumeni-Like Syndrome (LFLS), or the Chompret criteria for TP53 gene testing.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81404 TP53 (tumor protein 53) (e.g., tumor samples), targeted sequence analysis of 2-5 exons  81405 TP53 (tumor protein 53) (e.g., Li-Fraumeni syndrome, tumor samples), full gene sequence or targeted sequence analysis of >5 exons

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>TRG</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	TRG gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• Diagnosis and treatment of T-cell neoplasms.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81342 TRG@ (T cell antigen receptor, gamma) (e.g., leukemia and lymphoma), gene rearrangement analysis, evaluation to detect abnormal clonal populations

<b>GENE:</b>	<b>UPD</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	UPD gene testing is covered for the following indication: <ul style="list-style-type: none"> <li>• For neonates, infants, children or adults symptomatic for Beckwith-Wiedemann Syndrome (BWS) to diagnose Uniparental Disomy (UPD) for chromosome 11.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81402 Uniparental disomy (UPD) (e.g., Russell-Silver syndrome, Prader-Willi/Angelman syndrome), short tandem repeat (STR) analysis

<b>GENE:</b>	<b>UGT1A1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	UGT1A1 gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Prior to irinotecan administration in patients with CRC to lower the starting dose of irinotecan in patients with the UGT1A1*28/UGT1A1*28 genotype.</li> <li>• Prior to irinotecan administration in patients with CRC to increase the starting dose of irinotecan in patients with the UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*28 genotypes.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81350 UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (e.g., irinotecan metabolism), gene analysis, common variants (e.g., *28, *36, *37)

<b>GENE:</b>	<b>VHL</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	VHL gene testing is covered for the following indications: <ul style="list-style-type: none"> <li>• Diagnosis of Von Hippel-Lindau (VHL) syndrome in patients presenting with pheochromocytoma, paraganglioma, or central nervous system hemangioblastoma.</li> <li>• Confirmation of diagnosis in individuals with symptoms consistent with VHL syndrome.</li> </ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81403 VHL (von Hippel-Lindau tumor suppression) (e.g., von Hippel-Lindau familial cancer syndrome), deletion/duplication analysis  81404 VHL (Von Hippel-Lindau tumor suppression) (e.g., von Hippel-Lindau familial cancer syndrome), full gene sequence

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

**TRICARE Operations Manual 6010.56-M, February 1, 2008**

Chapter 18, Section 17

Defense Health Agency (DHA) Evaluation Of Non-United States Food and Drug Administration (FDA)  
Approved Laboratory Developed Tests (LDTs) Demonstration Project

**FIGURE 18.17-1 APPROVED LABORATORY DEVELOPED TESTS (LDTs) BY TEST NAME OR BY GENE(S) TESTED (CONTINUED)**

<b>GENE:</b>	<b>VKORC1</b>	
Effective Date:	January 1, 2013	
Coverage Guidelines:	VKORC1 gene testing is covered for the following indication: <ul style="list-style-type: none"><li>• For the initiation and management of warfarin treatment.</li></ul>	
CPT Coding When Clinically Indicated By Coverage Guidelines:	CPT <sup>1</sup> Code	81355 VKORC1 gene
<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.		

- END -

